Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04458051|
Recruitment Status : Recruiting
First Posted : July 7, 2020
Last Update Posted : February 1, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)
To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relationship to efficacy and safety To evaluate pharmacodynamics of SAR442168
|Condition or disease||Intervention/treatment||Phase|
|Primary Progressive Multiple Sclerosis||Drug: Tolebrutinib Drug: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||990 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)|
|Actual Study Start Date :||August 13, 2020|
|Estimated Primary Completion Date :||August 2024|
|Estimated Study Completion Date :||August 2024|
Dose 1 of oral SAR442168 daily
Pharmaceutical form: Film-coated Tablet Route of administration: Oral
Other Name: SAR442168
Placebo Comparator: Placebo
Placebo to match the SAR442168 daily
Pharmaceutical form: Film-coated Tablet Route of administration: Oral
- 6 month Confirmed Disability Progression (CDP) [ Time Frame: Up to approximately 48 months ]
Time to onset of 6 month CDP defined as follows:
Increase of ≥1.0 point from the baseline expanded disability status scale (EDSS) score when the baseline score is ≤5.5, or Increase of ≥0.5 points when the baseline EDSS score is >5.5
- 3-month confirmed disability progression (CDP) [ Time Frame: Up to approximately 48 months ]Time to onset of 3-month CDP as assessed by EDSS score
- 3-month change in 9-hole peg test (9-HPT) [ Time Frame: Up to approximately 48 months ]Time to onset of sustained 20% increase in the 9-HPT test confirmed over at least 3 months
- 3-month change in timed 25 foot walk (T25-FW) [ Time Frame: Up to approximately 48 months ]Time to onset of sustained 20% increase in the T25-FW confirmed over at least 3 months
- Change in T2 hyperintense lesions by MRI [ Time Frame: From Baseline up to 48 approximately months ]Total number of new and/or enlarging T2 hyperintense lesions as detected by MRI after baseline up to and including the end of study (EOS)
- Time to onset of confirmed disability improvement (CDI) [ Time Frame: From Baseline up to 48 approximately months ]Time to onset of CDI defined as ≥1.0 point decrease on the EDSS score from baseline confirmed over at least 6 months
- Percent change in Brain volume loss (BVL) [ Time Frame: From 6 months up to approximately 48 months - ]Percent change in brain volume loss (BVL) as detected by brain MRI at the EOS compared to month 6
- Change in cognitive function as assessed by the Symbol Digit Modalities Test (SDMT) [ Time Frame: From Baseline up to approximately 48 months ]Change in cognitive function at the EOS compared to baseline as assessed by the SDMT
- Change in cognitive function as assessed by the California Verbal Learning Test II (CVLT-II) [ Time Frame: From Baseline up to approximately 48 months ]Change in cognitive function at the EOS compared to baseline as assessed by the CVLT-II
- Change in Multiple Sclerosis Quality of Life [ Time Frame: From Baseline up to approximately 48 months ]Change in Multiple Sclerosis Quality of Life-54 (MSQoL-54) at the EOS compared to baseline
- Safety and Tolerability [ Time Frame: From screening up to approximately 48 months ]Number of participants with adverse events (AEs), Serious AEs, AEs leading to permanent study intervention discontinuation, and adverse events of special interest (AESI)
- Population pharmacokinetics [ Time Frame: Months 6, 9 and 12 ]Plasma concentration of SAR442168 (population PK assessment) at Months 6, 9, and 12
- Change in plasma neurofilament light chain (NfL) [ Time Frame: From Baseline up to approximately 48 months ]Change in NfL levels from at the EOS compared to baseline
- Change in lymphocyte phenotype subsets [ Time Frame: From Baseline up to approximately 48 months ]Change in lymphocyte phenotype subsets in whole blood at the EOS compared to baseline in a subset of participants
- Changes in serum Immunoglobulin level [ Time Frame: From Baseline up to approximately 48 months ]Changes in serum Immunoglobulin level at the EOS compared to baseline
- Change in serum chitinase-3 like protein 1 (Chi3L1) [ Time Frame: From Baseline up to approximately 48 months - ]Change in serum chitinase-3 like protein 1 (Chi3L1) from baseline to EOS
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 55 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Inclusion criteria :
- 18 to 55 years of age inclusive
- Diagnosis of PPMS according to the 2017 McDonald criteria
- Expanded disability status scale (EDSS) between 2.0 to 6.5 points, inclusive at screening
- Disease duration from the onset of MS symptoms of <15 years if screening EDSS score of >5.0 OR <10 years if screening EDSS score of ≤5.0.
- Positive cerebrospinal fluid oligoclonal bands and/or elevated Immunoglobulin G (IgG) index either during screening or documented previous history.
- Contraceptive use consistent with local regulations for individuals participating in clinical studies
Participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- Is not a woman of child bearing potential (WOCBP) OR
- Is a WOCBP and agrees to use an acceptable contraceptive method
- Participant has conditions that would adversely affect study participation such as short life expectancy.
- Evidence of infection with human immunodeficiency virus (HIV), transplantation, progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infection that would adversely affect study participation.
- Persistent chronic or active or recurring system infection that may adversely affect participation or IMP administration in this study as judged by the investigator
- History of malignancy within 5 years prior to screening.
- History of alcohol or drug abuse within 1 year prior to Screening.
- Hospitalized for psychiatric disease within 2 years prior to Screening.
- Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at Screening.
- Bleeding disorder, known platelet dysfunction at any time prior to the screening visit
- A platelet count <150 000/μL at the screening visit.
- A history of significant bleeding event within 6 months prior to screening, according to the Investigator's judgment such as, but not limited to cerebral or gastrointestinal
- Lymphocyte count below the lower limit of normal at Screening.
- Recent live (attenuated) vaccine within 2 months before the first treatment visit.
- Recent major surgery (within 4 weeks of Screening) or planned major surgery during the study.
- The participant has received medications/treatments for MS within a specified time frame.
- Receiving potent and moderate inducers or inhibitors of cytochrome P450 3A (CYP3A) or potent inhibitors of CYP2C8 hepatic enzymes.
- Receiving anticoagulant or antiplatelet therapy (such as aspirin>81mg/day, clopidogrel, warfarin).
- Contraindications to magnetic resonance imaging (MRI).
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04458051
|Contact: Trial Transparency email recommended (Toll free number for US & Canada)||800-633-1610 ext option 6||Contact-US@sanofi.com|
|Study Director:||Clinical Sciences & Operations||Sanofi|
|Other Study ID Numbers:||
U1111-1238-1318 ( Other Identifier: UTN )
|First Posted:||July 7, 2020 Key Record Dates|
|Last Update Posted:||February 1, 2023|
|Last Verified:||January 17, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Multiple Sclerosis, Chronic Progressive
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Immune System Diseases